Activation of paraoxonase 1 after hemodialysis is associated with HDL remodeling and its increase in the HDL2 fraction and VLDL

Clinica Chimica Acta

Volumn 430, Issue , 2014, Pages 9-14

  Gugliucci, Alejandro ^a   Kinugasa, Eriko ^b   Ogata, Hiroaki ^b   Caccavello, Russell ^a   Kimura, Satoshi ^b  

^a TOURO UNIVERSITY CALIFORNIA   (United States)

^b SHOWA UNIVERSITY NORTHERN YOKOHAMA HOSPITAL   (Japan)

Author keywords

Arylesterase; Cardiovascular risk; Hemodialysis; High density lipoprotein subclasses; Lactonase; PON1

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN A2; APOLIPOPROTEIN E; ARYLDIALKYLPHOSPHATASE 1; ARYLESTERASE; GLUCONOLACTONASE; HIGH DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; VERY LOW DENSITY LIPOPROTEIN; ARYLDIALKYLPHOSPHATASE; PON1 PROTEIN, HUMAN;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME ACTIVITY; FEMALE; HEMODIALYSIS; HUMAN; KIDNEY FAILURE; LIPOLYSIS; LONG TERM CARE; MALE; MIDDLE AGED; PRIORITY JOURNAL; THERAPY EFFECT; DENATURING GRADIENT GEL ELECTROPHORESIS; METABOLISM; RENAL REPLACEMENT THERAPY; WESTERN BLOTTING;

ARYLDIALKYLPHOSPHATASE; BLOTTING, WESTERN; DENATURING GRADIENT GEL ELECTROPHORESIS; ENZYME ACTIVATION; FEMALE; HUMANS; LIPOPROTEINS, HDL; LIPOPROTEINS, VLDL; MALE; MIDDLE AGED; RENAL DIALYSIS;

EID: 84892414915     PISSN: 00098981     EISSN: 18733492     Source Type: Journal    
DOI: 10.1016/j.cca.2013.12.027     Document Type: Article

References (32)

1. Avramovic M., Stefanovic V. Health-related quality of life in different stages of renal failure. Artif Organs Jul 2012, 36(7):581-589.
2. Roy G.C., Sutradhar S.R., Barua U.K., et al. Cardiovascular complications of chronic renal failure - an updated review. Mymensingh Med J Jul 2012, 21(3):573-579.
3. Gugliucci A., Kotani K., Kimura S. Paraoxonase 1 in chronic kidney failure. J Lipids 2012, 2012:726048.
4. Aviram M. Atherosclerosis: cell biology and lipoproteins - paraoxonases protect against atherosclerosis and diabetes development. Curr Opin Lipidol Apr 2012, 23(2):169-171.
5. Aviram M., Vaya J. Paraoxonase 1 activities, regulation, and interactions with atherosclerotic lesion. Curr Opin Lipidol Aug 2013, 24(4):339-344.
6. Mackness M., Mackness B. Targeting paraoxonase-1 in atherosclerosis. Expert Opin Ther Targets Jul 2013, 17(7):829-837.
7. Mackness M.I., Arrol S., Durrington P.N. Paraoxonase prevents accumulation of lipoperoxides in low-density lipoprotein. FEBS Lett Jul 29 1991, 286(1-2):152-154.
8. Draganov D.I. Lactonases with organophosphatase activity: structural and evolutionary perspectives. Chem Biol Interact Sep 6 2010, 187(1-3):370-372.
9. Cacciagiu L.D., Gonzalez A.I., Gomez Rosso L., et al. HDL-associated enzymes and proteins in hemodialysis patients. Clin Biochem Feb 2012, 45(3):243-248.
10. Dirican M., Akca R., Sarandol E., Dilek K. Serum paraoxonase activity in uremic predialysis and hemodialysis patients. J Nephrol Nov-Dec 2004, 17(6):813-818.
11. Dronca M., Pasca S.P., Nemes B., Vlase L., Vladutiu D. Serum paraoxonase 1 activities and homocysteinemia in hemodialysis patients. CCLM/FESCC 2008, 46(6):880-881.
12. Itahara T., Suehiro T., Ikeda Y., et al. Serum paraoxonase and arylesterase activities in hemodialysis patients. J Atheroscler Thromb 2000, 7(3):152-158.
13. Suehiro T., Ikeda Y., Shiinoki T., et al. Serum paraoxonase (PON1) concentration in patients undergoing hemodialysis. J Atheroscler Thromb 2002, 9(3):133-138.
14. Peti A., Csiky B., Guth E., et al. Associations of adiponectin with paraoxonase 1 and sE-selectin in hemodialyzed patients. Kidney Blood Press Res 2009, 32(5):360-365.
15. Sztanek F., Seres I., Harangi M., et al. Decreased paraoxonase 1 (PON1) lactonase activity in hemodialyzed and renal transplanted patients. A novel cardiovascular biomarker in end-stage renal disease. Nephrol Dial Transplant Jul 2012, 27(7):2866-2872.
16. Varga E., Seres I., Harangi M., et al. Serum cystatin C is a determinant of paraoxonase activity in hemodialyzed and renal transplanted patients. Dis Markers 2009, 26(3):141-148.
17. Gugliucci A., Kinugasa E., Kotani K., Caccavello R., Kimura S. Serum paraoxonase 1 (PON1) lactonase activity is lower in end-stage renal disease patients than in healthy control subjects and increases after hemodialysis. Clin Chem Lab Med CCLM/FESCC Jan 2011, 49(1):61-67.
18. Gugliucci A., Lunceford N., Kinugasa E., Ogata H., Schulze J., Kimura S. Acrolein inactivates paraoxonase 1: changes in free acrolein levels after hemodialysis correlate with increases in paraoxonase 1 activity in chronic renal failure patients. Clin Chim Acta Sep 2007, 384(1-2):105-112.
19. Gugliucci A., Mehlhaff K., Kinugasa E., et al. Paraoxonase-1 concentrations in end-stage renal disease patients increase after hemodialysis: correlation with low molecular AGE adduct clearance. Clin Chim Acta Feb 2007, 377(1-2):213-220.
20. Gugliucci A., Schulze J., Kinugasa E., Ogata H., Kimura S. The free fraction of paraoxonase 1 is not increased in patients with end stage renal disease undergoing hemodialysis. Clin Chim Acta Apr 2009, 402(1-2):209-210.
21. Kotani K., Kimura S., Gugliucci A. Paraoxonase-1 and ischemia-modified albumin in patients with end-stage renal disease. J Physiol Biochem Sep 2011, 67(3):437-441.
22. Horoz M., Kiykim A.A., Cimen B., Erdem A. The influence of hemodialysis membrane permeability on serum paraoxonase-1 activity and oxidative status parameters. Artif Organs Oct 2011, 35(10):923-929.
23. Ribeiro S., do Sameiro Faria M., Mascarenhas-Melo F., et al. Main determinants of PON1 activity in hemodialysis patients. Am J Nephrol 2012, 36(4):317-323.
24. Prakash M., Phani N.M., Kavya R., Supriya M. Paraoxonase: its antiatherogenic role in chronic renal failure. Ind J Nephrol Jan 2010, 20(1):9-14.
25. Gugliucci A., Caccavello R., Kotani K., Sakane N., Kimura S. Enzymatic assessment of paraoxonase 1 activity on HDL subclasses: a practical zymogram method to assess HDL function. Clin Chim Acta Jan 16 2013, 415:162-168.
26. Kennedy D.J., Tang W.H., Fan Y., et al. Diminished antioxidant activity of high-density lipoprotein-associated proteins in chronic kidney disease. J Am Heart Assoc Apr 2013, 2(2):e000104.
27. Orsoni A., Saheb S., Levels J.H., et al. LDL-apheresis depletes apoE-HDL and pre-beta1-HDL in familial hypercholesterolemia: relevance to atheroprotection. J Lipid Res 2011 Dec, 52(12):2304-2313.
28. Umaerus M., Rosengren B., Fagerberg B., Hurt-Camejo E., Camejo G. HDL2 interferes with LDL association with arterial proteoglycans: a possible athero-protective effect. Atherosclerosis 2012 Nov, 225(1):115-120.
29. Gugliucci A. Activation of paraoxonase 1 is associated with HDL remodeling ex vivo. Clin Chim Acta 2013, 429:38-45.
30. Deakin S., Moren X., James R.W. Very low density lipoproteins provide a vector for secretion of paraoxonase-1 from cells. Atherosclerosis Mar 2005, 179(1):17-25.
31. Rosenblat M., Ward S., Volkova N., Hayek T., Aviram M. VLDL triglycerides inhibit HDL-associated paraoxonase 1 (PON1) activity: in vitro and in vivo studies. Biofactors Jul-Aug 2012, 38(4):292-299.
32. Manning P.J., Jong S.A., Ryalls A.R., Sutherland W.H. Paraoxonase 1 activity in chylomicrons and VLDL: the effect of type 2 diabetes and meals rich in saturated fat and oleic acid. Lipids 2012 Mar, 47(3):259-267.